TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy

descriptionPublicationkeyboard_double_arrow_right Article 01 Mar 2023 English Publisher:Elsevier BVJournal:Trends in Immunology, volume 44, pages 156-158 (issn: 1471-4906,

Copyright policy )

Authors: Michelle A. Kelliher; Katherine A. Fitzgerald;

doi: 10.1016/j.it.2023.01.009

pmid: 36740513

TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy

- Summary
- Subjects
- Metrics

Abstract

Resistance mechanisms have curbed the potential of immune checkpoint blockade (ICB) therapies. Understanding mechanisms that contribute to this resistance should reveal new targets for combinatorial therapy. Tank-binding kinase 1 (TBK1) represents such a target. In recent work by Sun et al., inhibition of TBK1 restored the efficacy of such treatments by sensitizing tumors to RIPK1 kinase-dependent inflammatory cell death.

Related Organizations

University of Massachusetts Medical School
United States
University of Massachusetts System
United States

Keywords

Cell Death, Neoplasms, Receptor-Interacting Protein Serine-Threonine Kinases, Humans, Immunotherapy, Protein Serine-Threonine Kinases

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%